BR112018069785A2 - formas de dosagem dissuasivas de abuso de liberação prolongada - Google Patents
formas de dosagem dissuasivas de abuso de liberação prolongadaInfo
- Publication number
- BR112018069785A2 BR112018069785A2 BR112018069785A BR112018069785A BR112018069785A2 BR 112018069785 A2 BR112018069785 A2 BR 112018069785A2 BR 112018069785 A BR112018069785 A BR 112018069785A BR 112018069785 A BR112018069785 A BR 112018069785A BR 112018069785 A2 BR112018069785 A2 BR 112018069785A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage forms
- dissuasive
- prolonged release
- release abuse
- controlled release
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 230000002035 prolonged effect Effects 0.000 title 1
- 238000013270 controlled release Methods 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000009474 hot melt extrusion Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção refere-se a formas de dosagem dissuasivas de abuso e liberação prolongada que compreendem partículas de liberação controlada resistentes ao esmagamento que proveem propriedades dissuasivas de abuso às formas de dosagem. as partículas de liberação controlada resistentes ao esmagamento, que compreendem polímeros plásticos/elásticos e pelo menos um ingrediente farmacêutico ativo (api) ou um sal farmaceuticamente aceitável deste, são preparadas por um processo de extrusão por fusão a quente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662315952P | 2016-03-31 | 2016-03-31 | |
PCT/US2017/023316 WO2017172406A1 (en) | 2016-03-31 | 2017-03-21 | Extended release, abuse deterrent dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018069785A2 true BR112018069785A2 (pt) | 2019-01-29 |
Family
ID=59958479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018069785A BR112018069785A2 (pt) | 2016-03-31 | 2017-03-21 | formas de dosagem dissuasivas de abuso de liberação prolongada |
Country Status (8)
Country | Link |
---|---|
US (3) | US10624888B2 (pt) |
EP (1) | EP3435984A4 (pt) |
JP (2) | JP7023859B2 (pt) |
AU (1) | AU2017241266B2 (pt) |
BR (1) | BR112018069785A2 (pt) |
CA (1) | CA3019335A1 (pt) |
MX (1) | MX2018011799A (pt) |
WO (1) | WO2017172406A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3019335A1 (en) * | 2016-03-31 | 2017-10-05 | SpecGx LLC | Extended release, abuse deterrent dosage forms |
EP3672575A1 (en) * | 2017-08-25 | 2020-07-01 | Eleonor SPRL | Composition comprising at least one protoberberine alkaloid and its production process |
MX2021002459A (es) * | 2018-09-25 | 2021-04-29 | SpecGx LLC | Formas de dosificacion en capsula disuasorias del abuso de liberacion inmediata. |
BE1028182B1 (fr) * | 2020-04-17 | 2022-03-28 | Eleonor | Composition comprenant au moins un alcaloïde de protoberbérine et son procédé de fabrication |
CN114073252B (zh) * | 2020-08-12 | 2022-11-08 | 中国热带农业科学院环境与植物保护研究所 | 荔枝用展着剂及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ES2325046T3 (es) | 1996-06-26 | 2009-08-24 | The Board Of Regents, The University Of Texas System | Formulacion farmaceutica extruible por fusion en caliente. |
DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
KR20040060917A (ko) | 2001-08-06 | 2004-07-06 | 유로-셀티크 소시에떼 아노뉨 | 오피오이드 남용을 방지하기 위한 조성물 및 방법 |
CA2464528A1 (en) * | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
ES2733044T1 (es) * | 2002-04-05 | 2019-11-27 | Mundipharma Pharmaceuticals S L | Composición farmacéutica que contiene oxicodona y naloxona |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
TWI350762B (en) | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
FR2881652B1 (fr) | 2005-02-08 | 2007-05-25 | Flamel Technologies Sa | Forme pharmaceutique orale microparticulaire anti-mesuage |
SG169334A1 (en) * | 2006-01-21 | 2011-03-30 | Abbott Gmbh & Co Kg | Dosage form and method for the delivery of drugs of abuse |
US20080069891A1 (en) | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) * | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
DE102007028869A1 (de) * | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil |
BRPI0906467C1 (pt) | 2008-01-25 | 2021-05-25 | Gruenenthal Gmbh | forma de dosagem farmacêutica com formato exterior modificado resistente à ruptura e com liberação controlada |
US10751287B2 (en) * | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
CA2917136C (en) * | 2013-07-12 | 2022-05-31 | Grunenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA3019335A1 (en) | 2016-03-31 | 2017-10-05 | SpecGx LLC | Extended release, abuse deterrent dosage forms |
-
2017
- 2017-03-21 CA CA3019335A patent/CA3019335A1/en active Pending
- 2017-03-21 MX MX2018011799A patent/MX2018011799A/es unknown
- 2017-03-21 WO PCT/US2017/023316 patent/WO2017172406A1/en active Application Filing
- 2017-03-21 JP JP2018550680A patent/JP7023859B2/ja active Active
- 2017-03-21 BR BR112018069785A patent/BR112018069785A2/pt not_active Application Discontinuation
- 2017-03-21 AU AU2017241266A patent/AU2017241266B2/en active Active
- 2017-03-21 US US15/464,865 patent/US10624888B2/en active Active
- 2017-03-21 EP EP17776311.7A patent/EP3435984A4/en active Pending
-
2020
- 2020-03-13 US US16/818,528 patent/US11446293B2/en active Active
-
2022
- 2022-02-09 JP JP2022018691A patent/JP7366170B2/ja active Active
- 2022-09-16 US US17/946,243 patent/US20230079134A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3435984A1 (en) | 2019-02-06 |
US10624888B2 (en) | 2020-04-21 |
US20230079134A1 (en) | 2023-03-16 |
US11446293B2 (en) | 2022-09-20 |
US20170281615A1 (en) | 2017-10-05 |
EP3435984A4 (en) | 2019-11-06 |
JP2022051901A (ja) | 2022-04-01 |
MX2018011799A (es) | 2019-01-24 |
JP7023859B2 (ja) | 2022-02-22 |
WO2017172406A1 (en) | 2017-10-05 |
AU2017241266B2 (en) | 2022-02-10 |
CA3019335A1 (en) | 2017-10-05 |
US20200268747A1 (en) | 2020-08-27 |
AU2017241266A1 (en) | 2018-10-18 |
JP7366170B2 (ja) | 2023-10-20 |
JP2019510040A (ja) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018069785A2 (pt) | formas de dosagem dissuasivas de abuso de liberação prolongada | |
WO2017205844A3 (en) | Materials architecture for gastric residence systems | |
EP3309177A4 (en) | Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof | |
EP3478363A4 (en) | CONTROLLED RELEASE OF AMPHETAMINE, PROMOTER AND DISSUASIVE DOSAGE FORMS OF MISUSE | |
PE20160606A1 (es) | Formas de dosificacion granuladas disuasivas del abuso de liberacion inmediata | |
WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
MA45472A (fr) | Systèmes d'administration pour la libération contrôlée de médicaments | |
BR112019004911A2 (pt) | oligonucleotídeos modificados e métodos de uso | |
BR112016022214A2 (pt) | rnase para uso no tratamento ou prevenção de infecções virais | |
EP3381472A4 (en) | MEDICINAL PRODUCTS FOR THE TREATMENT OR PREVENTION OF DISTURBANCES CAUSED BY TGF SIGNALS AND USE THEREOF | |
WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
MA42458A (fr) | Systèmes améliorés d'administration de nanoparticules | |
DK3630061T3 (da) | Udfældningsresistente, småmolekylære lægemiddelformuleringer | |
EP3539978A4 (en) | NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION WITH IT AS THE ACTIVE INGREDIENT | |
PH12018501758A1 (en) | Oritavancin formulations | |
BR112016017644A2 (pt) | conjugados de fator vii | |
WO2017079403A3 (en) | Polymeric nanoparticles | |
BR112018010767A2 (pt) | revestimento comestível, sistema de produtos comestíveis apresentando o referido revestimento comestível e uso do referido sistema | |
WO2016103042A8 (en) | Compositions and methods for inhibiting expression of adamts-5 and adam17 | |
FR3038840B1 (fr) | Dispositif de securite pour une seringue d'injection. | |
FR3019047B1 (fr) | Diffuseur d'agent parfumant et/ou assainissant active par retournement. | |
EP3659626A4 (en) | MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF CONDITIONS RELATED TO THE TGF- SIGNALING ROUTE, AND ITS APPLICATION | |
EP3564373A4 (en) | THERAPEUTIC DRUG FOR ALPORT SYNDROME | |
UA118032U (uk) | Фармацевтична композиція | |
TH1701002334A (th) | โครเมนซึ่งถูกแทนที่และวิธีการใช้ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |